In PIONEER 6, unadjudicated DRP occurred in 5.8% of oral semaglutide-treated patients and in 4.8% of the placebo-treated patients ( Villsbol and colleagues further investigated the DRP signal in the SUSTAIN program (122)
Medically Reviewed By Board-Certified Addiction Medicine Physician with 30+ years of treatment experience Private Insurance Accepted Locations Merchantville, NJ | Virginia Beach, VA | Dallas, TX and now Nationwide
Based on this feedback, below are the key recommendations for payers looking to manage GLP-1s into 2026 and beyond: Require a recorded diagnosis code for GLP-1 prior authorizations
These are not FDA-approved
This surge coincided with Zepbounds approval for OSA, marking the largest observed difference in uptake between patients with and without a comorbidity
Find articles by Trzaskalski, N